Loss of β-cell identity occurs in type 2 diabetes and is associated with islet amyloid deposits

Diabetes

Volumn 64, Issue 8, 2015, Pages 2928-2938

  Spijker, H Siebe ^a   Song, Heein ^a,b   Ellenbroek, Johanne H ^a   Roefs, Maaike M ^a   Engelse, Marten A ^a   Bos, Erik ^a   Koster, Abraham J ^a   Rabelink, Ton J ^a   Hansen, Barbara C ^c   Clark, Anne ^d   Carlotti, Françoise ^a   De Koning, Eelco J P ^a,e  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Korea Advanced Institute of Science and Technology (KAIST)   (South Korea)

^c UNIVERSITY OF SOUTH FLORIDA   (United States)

^d CHURCHILL HOSPITAL   (United Kingdom)

^e HUBRECHT INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID; CELL MARKER; GLUCAGON; INSULIN; PROTEIN ARX; TRANSCRIPTION FACTOR FKHR; TRANSCRIPTION FACTOR MAFA; TRANSCRIPTION FACTOR NKX6.1; TRANSCRIPTION FACTOR PDX 1; UNCLASSIFIED DRUG;

ADULT; AMYLOIDOSIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL LOSS; CELLULAR DISTRIBUTION; CONTROLLED STUDY; EX VIVO STUDY; HORMONE RELEASE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; MACACA FASCICULARIS; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RHESUS MONKEY; AMYLOID PLAQUE; ANIMAL; METABOLISM; PANCREAS ISLET ALPHA CELL; PATHOLOGY; PATHOPHYSIOLOGY;

ANIMALS; DIABETES MELLITUS, TYPE 2; GLUCAGON; GLUCAGON-SECRETING CELLS; HUMANS; INSULIN; INSULIN-SECRETING CELLS; ISLETS OF LANGERHANS; MACACA FASCICULARIS; MACACA MULATTA; MALE; PLAQUE, AMYLOID;

EID: 84942877373     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db14-1752     Document Type: Article

References (51)

1. Prentki M, Nolan CJ. Islet beta cell failure in type 2 diabetes. J Clin Invest 2006;116:1802-1812
2. Bonner-Weir S, O'Brien TD. Islets in type 2 diabetes: in honor of Dr. Robert C. Turner. Diabetes 2008;57:2899-2904
3. Del Guerra S, Lupi R, Marselli L, et al. Functional and molecular defects of pancreatic islets in human type 2 diabetes. Diabetes 2005;54:727-735
4. Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC. β-cell deficit and increased β-cell apoptosis in humans with type 2 diabetes. Diabetes 2003;52:102-110
5. Rahier J, Guiot Y, Goebbels RM, Sempoux C, Henquin JC. Pancreatic betacell mass in European subjects with type 2 diabetes. Diabetes Obes Metab 2008;10(Suppl. 4):32-42
6. de Koning EJ, Bonner-Weir S, Rabelink TJ. Preservation of beta-cell function by targeting beta-cell mass. Trends Pharmacol Sci 2008;29:218-227
7. Gromada J, Franklin I, Wollheim CB. Alpha-cells of the endocrine pancreas: 35 years of research but the enigma remains. Endocr Rev 2007;28:84-116
8. Talchai C, Xuan S, Lin HV, Sussel L, Accili D. Pancreatic β cell dedifferentiation as a mechanism of diabetic b cell failure. Cell 2012;150:1223-1234
9. Dor Y, Glaser B. β-cell dedifferentiation and type 2 diabetes. N Engl J Med 2013;368:572-573
10. Spijker HS, Ravelli RB, Mommaas-Kienhuis AM, et al. Conversion of mature human β-cells into glucagon-producing α-cells. Diabetes 2013;62:2471-2480
11. Szabat M, Lynn FC, Hoffman BG, Kieffer TJ, Allan DW, Johnson JD. Maintenance of β-cell maturity and plasticity in the adult pancreas: developmental biology concepts in adult physiology. Diabetes 2012;61:1365-1371
12. Pagliuca FW, Melton DA. How to make a functional β-cell. Development 2013;140:2472-2483
13. Guo S, Dai C, Guo M, et al. Inactivation of specific β cell transcription factors in type 2 diabetes. J Clin Invest 2013;123:3305-3316
14. Butler AE, Robertson RP, Hernandez R, Matveyenko AV, Gurlo T, Butler PC. Beta cell nuclear musculoaponeurotic fibrosarcoma oncogene family A (MafA) is deficient in type 2 diabetes. Diabetologia 2012;55:2985-2988
15. Jonas JC, Sharma A, Hasenkamp W, et al. Chronic hyperglycemia triggers loss of pancreatic beta cell differentiation in an animal model of diabetes. J Biol Chem 1999;274:14112-14121
16. Hansen BC, Bodkin NL. Heterogeneity of insulin responses: phases leading to type 2 (non-insulin-dependent) diabetes mellitus in the rhesus monkey. Diabetologia 1986;29:713-719
17. de Koning EJ, Bodkin NL, Hansen BC, Clark A. Diabetes mellitus in Macaca mulatta monkeys is characterised by islet amyloidosis and reduction in beta-cell population. Diabetologia 1993;36:378-384
18. Ellenbroek JH, Töns HA, de Graaf N, et al. Topologically heterogeneous beta cell adaptation in response to high-fat diet in mice. PLoS One 2013;8:e56922
19. Ellenbroek JH, Töns HA, Westerouen van Meeteren MJ, et al. Glucagon-like peptide-1 receptor agonist treatment reduces beta cell mass in normoglycaemic mice. Diabetologia 2013;56:1980-1986
20. Clark A, Cooper GJ, Lewis CE, et al. Islet amyloid formed from diabetesassociated peptide may be pathogenic in type-2 diabetes. Lancet 1987;2:231-234
21. Peters PJ, Bos E, Griekspoor A. Cryo-immunogold electron microscopy. Curr Protoc Cell Biol 2006; Chapter 4:Unit 4.7
22. Clark A, Nilsson MR. Islet amyloid: a complication of islet dysfunction or an aetiological factor in type 2 diabetes? Diabetologia 2004;47:157-169
23. Henquin JC, Rahier J. Pancreatic alpha cell mass in European subjects with type 2 diabetes. Diabetologia 2011;54:1720-1725
24. Clark A, Wells CA, Buley ID, et al. Islet amyloid, increased A-cells, reduced B-cells and exocrine fibrosis: quantitative changes in the pancreas in type 2 diabetes. Diabetes Res 1988;9:151-159
25. Deng S, Vatamaniuk M, Huang X, et al. Structural and functional abnormalities in the islets isolated from type 2 diabetic subjects. Diabetes 2004;53:624-632
26. Unger RH, Cherrington AD. Glucagonocentric restructuring of diabetes: a pathophysiologic and therapeutic makeover. J Clin Invest 2012;122:4-12
27. Habener JF, Stanojevic V. Alpha cells come of age. Trends Endocrinol Metab 2013;24:153-163
28. Dunning BE, Gerich JE. The role of alpha-cell dysregulation in fasting and postprandial hyperglycemia in type 2 diabetes and therapeutic implications. Endocr Rev 2007;28:253-283
29. Hansen BC, Bodkin NL. Beta-cell hyperresponsiveness: earliest event in development of diabetes in monkeys. Am J Physiol 1990;259:R612-R617
30. Fiori JL, Shin YK, Kim W, et al. Resveratrol prevents β-cell dedifferentiation in non-human primates given a high-fat/high-sugar diet. Diabetes 2013;62:3500-3513
31. Westermark P, Andersson A, Westermark GT. Islet amyloid polypeptide, islet amyloid, and diabetes mellitus. Physiol Rev 2011;91:795-826
32. Jurgens CA, Toukatly MN, Fligner CL, et al. b-cell loss and β-cell apoptosis in human type 2 diabetes are related to islet amyloid deposition. Am J Pathol 2011;178:2632-2640
33. Zhang S, Liu H, Yu H, Cooper GJ. Fas-associated death receptor signaling evoked by human amylin in islet β-cells. Diabetes 2008;57:348-356
34. Park YJ, Woo M, Kieffer TJ, et al. The role of caspase-8 in amyloid-induced beta cell death in human and mouse islets. Diabetologia 2014;57:765-775
35. Sempoux C, Guiot Y, Dubois D, Moulin P, Rahier J. Human type 2 diabetes: morphological evidence for abnormal β-cell function. Diabetes 2001;50(Suppl. 1):S172-S177
36. Lorenzo A, Razzaboni B, Weir GC, Yankner BA. Pancreatic islet cell toxicity of amylin associated with type-2 diabetes mellitus. Nature 1994;368:756-760
37. Janson J, Ashley RH, Harrison D, McIntyre S, Butler PC. The mechanism of islet amyloid polypeptide toxicity is membrane disruption by intermediate-sized toxic amyloid particles. Diabetes 1999;48:491-498
38. Donath MY, Shoelson SE. Type 2 diabetes as an inflammatory disease. Nat Rev Immunol 2011;11:98-107
39. Masters SL, Dunne A, Subramanian SL, et al. Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1β in type 2 diabetes. Nat Immunol 2010;11:897-904
40. Westwell-Roper CY, Ehses JA, Verchere CB. Resident macrophages mediate islet amyloid polypeptide-induced islet IL-1β production and β-cell dysfunction. Diabetes 2014;63:1698-1711
41. Guardado-Mendoza R, Davalli AM, Chavez AO, et al. Pancreatic islet amyloidosis, beta-cell apoptosis, and alpha-cell proliferation are determinants of islet remodeling in type-2 diabetic baboons. Proc Natl Acad Sci U S A 2009;106:13992-13997
42. Yoneda S, Uno S, Iwahashi H, et al. Predominance of b-cell neogenesis rather than replication in humans with an impaired glucose tolerance and newly diagnosed diabetes. J Clin Endocrinol Metab 2013;98:2053-2061
43. Butler AE, Campbell-Thompson M, Gurlo T, Dawson DW, Atkinson M, Butler PC. Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors. Diabetes 2013;62:2595-2604
44. White MG, Marshall HL, Rigby R, et al. Expression of mesenchymal and α-cell phenotypic markers in islet β-cells in recently diagnosed diabetes. Diabetes Care 2013;36:3818-3820
45. Mezza T, Muscogiuri G, Sorice GP, et al. Insulin resistance alters islet morphology in nondiabetic humans. Diabetes 2014;63:994-1007
46. Cnop M, Hughes SJ, Igoillo-Esteve M, et al. The long lifespan and low turnover of human islet beta cells estimated by mathematical modelling of lipofuscin accumulation. Diabetologia 2010;53:321-330
47. Kjørholt C, Akerfeldt MC, Biden TJ, Laybutt DR. Chronic hyperglycemia, independent of plasma lipid levels, is sufficient for the loss of β-cell differentiation and secretory function in the db/db mouse model of diabetes. Diabetes 2005;54:2755-2763
48. Laybutt DR, Hawkins YC, Lock J, et al. Influence of diabetes on the loss of beta cell differentiation after islet transplantation in rats. Diabetologia 2007;50:2117-2125
49. Rezania A, Bruin JE, Riedel MJ, et al. Maturation of human embryonic stem cell-derived pancreatic progenitors into functional islets capable of treating preexisting diabetes in mice. Diabetes 2012;61:2016-2029
50. Weir GC, Bonner-Weir S. Islet β cell mass in diabetes and how it relates to function, birth, and death. Ann N Y Acad Sci 2013;1281:92-105
51. Ferrannini E. The stunned beta cell: a brief history. Cell Metab 2010;11:349-352